Bayer knowingly sold HIV-contaminated blood products to hemophiliacs in 1980s

When hemophiliacs across the globe began dying from AIDS in the 1980s, their families wanted answers. What they discovered was a deliberate choice by one of the world's largest pharmaceutical companies to prioritize profit over lives. Bayer, the German multinational conglomerate, had knowingly distributed HIV-contaminated blood clotting products to patients who had no way of protecting themselves.

Hemophiliacs depend on Factor VIII, a blood clotting agent, to survive. Without it, even minor injuries can be fatal. In the early 1980s, manufacturers like Bayer developed heat-treated versions of Factor VIII that killed the HIV virus, making the product safe. The company began selling this safer version domestically in the United States by the mid-1980s. But internationally, particularly in Latin America, Asia, and Europe, Bayer continued distributing the older, unheated product—the one that carried a known risk of HIV transmission.

Internal documents later revealed that Bayer executives were aware of the danger. The company had tested their products and knew which batches were contaminated. Some infected hemophiliacs reported that they were never informed of the risks. Instead, they trusted the pharmaceutical giant to provide them with safe medicine.

When the claims first emerged, Bayer's official position was straightforward denial. Company spokespeople argued that decisions about which products to sell where were based on market economics and regulatory differences between countries, not on any knowledge of contamination. They suggested that hemophiliacs contracted HIV through multiple potential sources, making it impossible to definitively link infections to Bayer's products. The implication was clear: these were conspiracy theories born from grief and desperation.

The evidence, however, told a different story. Investigative journalists, particularly those examining Bayer's internal communications, uncovered memos and emails showing that the company knew about the heat-treated alternative and its safety advantages. The New York Times reported in 2003 on "Two Paths of Bayer Drug in 80's: Riskier One Steered Overseas," documenting how Bayer deliberately chose to ship contaminated products internationally while selling the safer version at home. Court documents from subsequent lawsuits further corroborated these findings, with some cases resulting in settlements that implicitly acknowledged responsibility without admitting liability.